Özgeriş Fatma Betül, Kurt Nezahat, Ibili Ucuz Ilknur, Koçak Yilmaz Kübra, Keleş Mevlüt Sait, Çayir Atilla, Dursun Onur Burak
Department of Nutrition and Dietetics, Ataturk University School of Health Sciences, Turkey.
Department of Medical Biochemistry, Erzincan Binali Yildirim University School of Medicine, Turkey.
Eurasian J Med. 2022 Feb;54(1):50-53. doi: 10.5152/eurasianjmed.2022.21292.
Cognitive developmental delay is a picture of the group of early-onset chronic diseases that affect 1.5-10% of children. Autism spectrum disorders are neurodevelopmental diseases with a genetic basis and abnormal brain development, characterized by disorders in areas that make up interpersonal relationships, such as communication, social cognition, and processing of emotional signals. Immune system dysfunction is thought to play a role in the pathogenesis of some neurological disorders, including autism. Progranulin is thought to be a regulator of the innate immune response. The purpose of this study was to look at plasma levels of progranulin, an anti-inflammatory neurotrophic factor, in children with autism spectrum disorder and cognitive developmental delay.
The study was conducted on 52 children who were patients and 35 healthy children. Of the 52 children of the patient group, 32 were diagnosed with CDD and 20 were diagnosed with cognitive developmental delay-autism spectrum disorder. Serum progranulin concentrations were measured using a human-specific sandwich enzyme-linked immunosorbent assay.
Serum progranulin concentration was statistically lower in the patient group (110.746 ± 26.04) than in the healthy control group (137.346 ± 30.02). There was a statistically significant difference between the groups in levels of serum progranulin (P=.000). Receiver operating characteristic analysis was performed to evaluate the potential of progranulin as a biomarker to distinguish patients with cognitive developmental delay-autism spectrum disorder from healthy children. It detected a moderate area under the curve (0.743 ± 0.06) value and a more significant P value for progranulin (P=.000).
Progranulin deficiency in patients with autism spectrum disorder-cognitive developmental delay may result in decreased neurotrophic support for many years, with cumulative damage associated with unregulated inflammation that may play a role in autism spectrum disorder-cognitive developmental delay. We believe that low progranulin levels could be a biomarker for autism spectrum disorder-cognitive developmental delay.
认知发育迟缓是一组早发性慢性疾病的表现，影响1.5% - 10%的儿童。自闭症谱系障碍是具有遗传基础和大脑发育异常的神经发育疾病，其特征在于构成人际关系的领域存在障碍，如沟通、社会认知和情感信号处理。免疫系统功能障碍被认为在包括自闭症在内的一些神经疾病的发病机制中起作用。前颗粒蛋白被认为是先天性免疫反应的调节因子。本研究的目的是观察自闭症谱系障碍和认知发育迟缓儿童中抗炎神经营养因子前颗粒蛋白的血浆水平。
该研究对52名患病儿童和35名健康儿童进行。在52名患病儿童组中，32名被诊断为认知发育迟缓，20名被诊断为认知发育迟缓 - 自闭症谱系障碍。使用人特异性夹心酶联免疫吸附测定法测量血清前颗粒蛋白浓度。
患者组血清前颗粒蛋白浓度（110.746 ± 26.04）在统计学上低于健康对照组（137.346 ± 30.02）。两组血清前颗粒蛋白水平存在统计学显著差异（P = .000）。进行受试者工作特征分析以评估前颗粒蛋白作为区分认知发育迟缓 - 自闭症谱系障碍患者与健康儿童的生物标志物的潜力。它检测到曲线下面积适中（0.743 ± 0.06）值，且前颗粒蛋白的P值更显著（P = .000）。
自闭症谱系障碍 - 认知发育迟缓患者的前颗粒蛋白缺乏可能导致多年来神经营养支持减少，与未受调节的炎症相关的累积损伤可能在自闭症谱系障碍 - 认知发育迟缓中起作用。我们认为低前颗粒蛋白水平可能是自闭症谱系障碍 - 认知发育迟缓的生物标志物。
